Concurrent Use of Targeted Agents with Radiation and Chemotherapy
Track
:
PRES
Program Code:
PRES400
Date:
Sunday, September 21, 2008
Time:
2:45 PM to 4:00 PM
EST
Duration:
2715 Minutes
Location:
BCC Grand Ballroom
SPEAKER(S):
Arnab Chakravarti, M.D., Ohio State University
Hak Choy, Professor and Chairman, UT Southwestern Medical Center at Dallas
Specialties: Radiation Oncology
Dr. Hak Choy currently serves as the Nancy B and Jake L Hamon Distinguished Chair in Therapeutic Oncology Research at the prestigious University of Texas. In addition, Dr. Choy is the chair of the Lung Committee of the Radiation Therapy Oncology Group (RTOG). Dr Choy led the efforts to incorporate "the new generation" of cytotoxic chemotherapeutic agents with thoracic radiation. His contribution to the management of locally advanced NSCLC influenced the practice significantly. He is once again at the leading edge of two important areas of research in the treatment of locally advanced NSCLC - one to incorporate pemetrexed and another to redefine the optimal dose of radiation therapy. In the contemporary lung cancer arena, Dr Choy will be one among a select group of individuals making a significant and practice changing contribution to the field of lung cancer today.
Paul Harari, M.D., Professor, University of Wisconsin School of Medicine
Dr. Paul M. Harari is the Jack Fowler Professor and Chairman of the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health. Dr. Harari earned his Bachelors degree at Tufts University (1980) and Medical degree at the University of Virginia (1984). He completed his Internal Medicine Internship at the University of California Davis and Radiation Oncology Residency Training at the University of Arizona (1990). His clinical and laboratory research focuses primarily on treatment advances for head and neck cancer patients with emphasis on the interaction of molecular growth inhibitors combined with radiation. He serves as the Principal Investigator for a series of federal and industry sponsored research grants that examine the interaction of molecular growth inhibitors with radiation. Dr. Harari has served as Chairman of the ASTRO Education Committee (2004-2008) and on the ASCO Education and Program Committees. He directed the Radiation Oncology Residency Training Program at the University of Wisconsin from 1997-2007. Dr. Harari has authored over 150 original research articles and book chapters on cancer research topics with particular emphasis on the treatment of head and neck cancer.
Quynh-Thu Le , M.D. , Professor, Stanford University, Stanford, CA
I have had 10 years of experience working on approaches to identify hypoxia and modulate hypoxia in combination with radiation and chemotherapy. I have pulished over 60 peer reviewed manuscript on this topic. I have also conducted several phase I-II study using biologic targeted therapy in combination with radiation.
David Raben, M.D., Radiation Oncologist, University of Colorado Comprehensive Cancer Center
Dr. David Raben is a board certified radiation oncologist at the University of Colorado. Residency training in radiation oncology was conducted at the John Hopkins Hospital (1991-1994). Presently, he is a full professor and scientist in the only NCI-designated Comprehensive Cancer Center in the Rocky Mountain region at the University of Colorado Denver. Dr. Raben is nationally recognized regarding his work in targeted therapies and radiation, primarily in GI, head and neck cancer and lung cancer. He serves on the head and neck steering committee of the National Cancer Institute sponsored radiation cooperative group (RTOG). In addition, he is a member of the GU section of the SWOG and has extensive experience with both low dose (LDR) and high dose rate (HDR) brachytherapy. The UCD Radiation Oncology Dept. was the only site approved by the RTOG in Colorado to participate in the national phase II HDR brachytherapy trial. In addition, Dr Raben was the first radiation oncologist in the Rocky Mountain region to implement accelerated intensity modulated radiation to the prostate and pelvis, recently published in a peer-reviewed journal. His focus has also been on blocking critical growth, invasion and angiogenic signaling pathways driving cancer cells to enhance radiation therapy. He is an ad hoc reviewer for Cancer Research, Clinical Cancer Research, Head and Neck, Journal of Clinical Oncology and the International Journal of Radiation Oncology, Biology and Physics. He serves as the Director of the Radiological Sciences Core at the Cancer Center. Dr. Raben has contributed to 77 publications.